Form 4: Dyne Therapeutics CEO John Cox Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Dyne Therapeutics CEO John Cox sold 4,061 shares of common stock on March 5, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.
Summary
- On March 5, 2025, John Cox, CEO and President of Dyne Therapeutics, sold 4,061 shares of Dyne Therapeutics common stock at a price of $11.83 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units granted on December 4, 2024.
- The sale was automated as part of a pre-existing restricted stock unit agreement.
- Following the transaction, Mr. Cox directly owns 146,239 shares, including 136,219 unvested RSUs.
- Mr. Cox also indirectly owns 8,000 shares each through four different trusts for the benefit of his children.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and does not contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among executives of publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 12/04/2024 | Date of restricted stock units grant |
| 03/05/2025 | Date of stock sale |
| 03/07/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.